Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26728285 | 0.83 | P2RX7 (0.51) | P2RX7RAB9ANAMPTEPHX2MTNR1A | |
| SCHEMBL6925202 | 0.81 | P2RX7 (0.49) | P2RX7RAB9ANAMPTEPHX2ALDH1A1 | |
| SCHEMBL31036963 | 0.81 | P2RX7 (0.55) | P2RX7RAB9ANPC1NAMPTEPHX2 | |
| SCHEMBL23805008 | 0.80 | P2RX7 (0.48) | P2RX7RAB9ANPC1NAMPTEPHX2 | |
| SCHEMBL12500261 | 0.79 | CYP19A1 (0.47) | P2RX7RAB9AALDH1A1GALR3TSHR | |
| SCHEMBL8526169 | 0.78 | PPID (0.61) | P2RX7RAB9ANPC1ALDH1A1POLB | |
| SCHEMBL10630135 | 0.77 | GAA (0.53) | P2RX7ALDH1A1TSHRGAA | |
| SCHEMBL9848421 | 0.77 | HPGD (0.59) | P2RX7RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL9848458 | 0.77 | SOAT1 (0.49) | — | |
| SCHEMBL17787939 | 0.76 | ALDH1A1 (0.62) | RAB9ANPC1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113307777-B | Alogliptin benzoate intermediate and preparation method of Alogliptin benzoate | 石药集团欧意药业有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-113307777-A | Alogliptin benzoate intermediate and preparation method of Alogliptin benzoate | 石药集团欧意药业有限公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-110128401-B | Simple preparation method of alogliptin benzoate | 新发药业有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-110128401-A | A kind of simple and convenient process for preparing of alogliptin benzoate | 新发药业有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-105085475-B | A method of synthesis Egelieting intermediate | 上海科胜药物研发有限公司 | 2019-05-21 | — | — | CN | disclosed |
| EP-3118192-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| EP-2410855-B1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LTD (IL) | 2016-06-01 | — | — | EP | disclosed |
| CN-104086527-A | Synthetic method of alogliptin benzoate | HUNAN OUYA BIOLOG CO LTD | 2014-10-08 | — | — | CN | disclosed |
| US-8841447-B2 | Process for the preparation of alogliptin | MAPI PHARMA LTD. (IL) | 2014-09-23 | — | — | US | disclosed |
| US-20120029000-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LIMITED (IL) | 2012-02-02 | — | — | US | disclosed |
| WO-2010109468-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA HK LIMITED (CN) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029000-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | DPP7, DPP4, DPP8 | P2RX7 661/4885RAB9A 3644/4885NPC1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.